Astrazeneca plc ADR (NASDAQ: AZN)’s stock price has gone rise by 0.04 in comparison to its previous close of 69.85, however, the company has experienced a -1.08% decrease in its stock price over the last five trading days. fool.com reported 2025-06-28 that What’s the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
Astrazeneca plc ADR (NASDAQ: AZN) has a higher price-to-earnings ratio of 28.07x compared to its average ratio, The 36-month beta value for AZN is at 0.38. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B, and currently, shorts hold a 0.24% of that float. The average trading volume for AZN on July 01, 2025 was 5.28M shares.
AZN’s Market Performance
AZN’s stock has seen a -1.08% decrease for the week, with a -1.40% drop in the past month and a -5.30% fall in the past quarter. The volatility ratio for the week is 1.00%, and the volatility levels for the past 30 days are at 1.42% for Astrazeneca plc ADR The simple moving average for the last 20 days is -2.80% for AZN’s stock, with a simple moving average of -2.00% for the last 200 days.
Analysts’ Opinion of AZN
Many brokerage firms have already submitted their reports for AZN stocks, with Exane BNP Paribas repeating the rating for AZN by listing it as a “Outperform.” The predicted price for AZN in the upcoming period, according to Exane BNP Paribas is $75 based on the research report published on April 15, 2025 of the current year 2025.
AZN Trading at -0.90% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.30% of loss for the given period.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.81 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.14. The total capital return value is set at 0.14. Equity return is now at value 19.81, with 7.45 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 0.77. The interest coverage ratio of the stock is 7.95.
Currently, EBITDA for the company is 15.44 billion with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 4.4. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.90.
Conclusion
In conclusion, Astrazeneca plc ADR (AZN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
